LEXXLexaria Bioscience Corp.

Nasdaq www.lexariabioscience.com


$ 3.37 $ 0.26 (8.31 %)    

Monday, 09-Sep-2024 15:58:04 EDT
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 3.39
$ 3.23
$ 3.37 x 100
-- x --
$ 3.23 - $ 3.42
$ 0.85 - $ 6.85
62,840
na
53.6M
$ 1.64
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-12-2024 05-31-2024 10-Q
2 04-09-2024 02-29-2024 10-Q
3 01-12-2024 11-30-2023 10-Q
4 11-20-2023 08-31-2023 10-K
5 07-14-2023 05-31-2023 10-Q
6 04-14-2023 02-28-2023 10-Q
7 01-17-2023 11-30-2022 10-Q
8 11-28-2022 08-31-2022 10-K
9 07-14-2022 05-31-2022 10-Q
10 04-11-2022 02-28-2022 10-Q
11 01-14-2022 11-30-2021 10-Q
12 11-27-2021 08-31-2021 10-K
13 07-15-2021 05-31-2021 10-Q
14 04-14-2021 02-28-2021 10-Q
15 01-14-2021 11-30-2020 10-Q
16 10-15-2020 08-31-2020 10-K
17 06-30-2020 05-31-2020 10-Q
18 04-03-2020 02-29-2020 10-Q
19 01-09-2020 11-30-2019 10-Q
20 11-14-2019 08-31-2019 10-K
21 07-08-2019 05-31-2019 10-Q
22 04-15-2019 02-28-2019 10-Q
23 01-11-2019 11-30-2018 10-Q
24 11-14-2018 08-31-2018 10-K
25 07-13-2018 05-31-2018 10-Q
26 04-12-2018 02-28-2018 10-Q
27 01-12-2018 11-30-2017 10-Q
28 11-27-2017 08-31-2017 10-K
29 07-14-2017 05-31-2017 10-Q
30 04-14-2017 02-28-2017 10-Q
31 01-13-2017 11-30-2016 10-Q
32 11-29-2016 08-31-2016 10-K
33 07-13-2016 05-31-2016 10-Q
34 04-13-2016 02-29-2016 10-Q
35 01-08-2016 11-30-2015 10-Q
36 11-27-2015 08-31-2015 10-K
37 07-14-2015 05-31-2015 10-Q
38 04-14-2015 02-28-2015 10-Q
39 01-14-2015 11-30-2014 10-Q
40 09-11-2014 07-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Absorption improvements appear to continue with DehydraTECH-processed Rybelsus® vs. Rybelsus® tablets even under "fed" ...

 hc-wainwright--co-reiterates-buy-on-lexaria-bioscience-maintains-10-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Lexaria Bioscience (NASDAQ:LEXX) with a Buy and maintains $10 price target.

 interim-body-weight-results-from-lexarias-diabetes-animal-study-says-dehydratech-appears-to-work-with-a-second-glp-1-drug-liraglutide-dehydratech-cbd-is-showing-strong-apparent-performance-relative-to-glp-1-appears-to-be-working-with-semaglutide-both-with-and-without-snac-technology

- Reuters 

Core News & Articles

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug d...

 lexaria-bioscience-q3-eps-013-misses-010-estimate-sales-8400k-miss-15000k-estimate

Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of ...

 hc-wainwright--co-initiates-coverage-on-lexaria-bioscience-with-buy-rating-announces-price-target-of-10

HC Wainwright & Co. analyst Yi Chen initiates coverage on Lexaria Bioscience (NASDAQ:LEXX) with a Buy rating and announc...

Core News & Articles

Lexaria currently holding 46 granted patents worldwideKELOWNA, BC / ACCESSWIRE / July 8, 2024 / Lexaria Bioscience Corp. (NASDA...

Core News & Articles

First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral formatKELOWNA, BC / ACCESSWIRE / M...

Core News & Articles

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug d...

Core News & Articles

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug d...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION